SamulskiRJ, ChangLS, ShenkT. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol, 1989; 63:3822–3828.
2.
MendellJR, Al-ZaidySA, Rodino-KlapacLR, et al.Current clinical applications of in vivo gene therapy with AAVs. Mol Ther, 2021; 29:464–488.
3.
TranNT, LecomteE, SaleunS, et al.Human and insect cell-produced recombinant adeno-associated viruses show differences in genome heterogeneity. Hum Gene Ther, 2022; 33:371–388.
4.
LiL, DimitriadisEK, YangY, et al.Production and characterization of novel recombinant adeno-associated virus replicative-form genomes: a eukaryotic source of DNA for gene transfer. PLoS One, 2013; 8:e69879.
5.
KondratovO, MarsicD, CrossonSM, et al.Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells. Mol Ther, 2017; 25:2661–2675.
6.
RumachikNG, MalakerSA, PoweleitN, et al.Methods matter: standard production platforms for recombinant AAV produce chemically and functionally distinct vectors. Mol Ther Methods Clin Dev, 2020; 18:98–118.
7.
BernsKI. The unusual properties of the AAV inverted terminal repeat. Hum Gene Ther, 2020; 31:518–523.
8.
WornerTP, BennettA, HabkaS, et al.Adeno-associated virus capsid assembly is divergent and stochastic. Nat Commun, 2021; 12:1642.
9.
BennettA, HullJ, JolinonN, et al.Comparative structural, biophysical, and receptor binding study of true type and wild type AAV2. J Struct Biol, 2021; 213:107795.
10.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
11.
MietzschM, GrasseS, ZurawskiC, et al.OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1–12 vectors for gene therapy. Hum Gene Ther, 2014; 25:212–222.
12.
D'CostaS, BlouinV, BroucqueF, et al.Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol Ther Methods Clin Dev, 2016; 5:16019.
13.
GeorgeLA. Hemophilia gene therapy: ushering in a new treatment paradigm?. Hematol Am Soc Hematol Educ Program, 2021; 2021:226–233.
14.
HirschML, WolfSJ, SamulskiRJ. Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol Biol, 2016; 1382:21–39.
15.
DongB, NakaiH, XiaoW. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther, 2010; 18:87–92.
16.
HirschML, Agbandje-McKennaM, SamulskiRJ. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther, 2010; 18:6–8.
17.
NguyenGN, EverettJK, KafleS, et al.A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol, 2021; 39:47–55.
18.
KingJA, DubielzigR, GrimmD, et al.DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J, 2001; 20:3282–3291.
19.
BernsKI, MuzyczkaN. AAV: an overview of unanswered questions. Hum Gene Ther, 2017; 28:308–313.
20.
ZhangJ, YuX, GuoP, et al.Satellite subgenomic particles are key regulators of adeno-associated virus life cycle. Viruses, 2021; 13:1185.
21.
NiTH, ZhouX, McCartyDM, et al.In vitro replication of adeno-associated virus DNA. J Virol, 1994; 68:1128–1138.
